Phase 1 N=32 A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
Atopic Dermatitis
Primary: Cmax of OPA-15406 in a Single Administration Period — 0.508; 0.838; 1.61 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
Hearing Impairment
Primary: Maximum Effective Sound Pressure Level (MEPO) — 95 decibels (dB) Sound Pressure Level (SPL)
Phase 3 N=53 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Regional Neuroblastoma
Primary: Number of Responders — 21; 11 participants — p=0.0044
Phase 1 N=20 Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
Schizophrenia
Primary: Change From Baseline in Spatial Span Test Score — -0.199; 0.033; -0.066 score on a scale — p=0.753
Phase 2 N=143 Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Primary: Brief Pain Index - Item 5, Average Daily Pain Score (Range 0-10) Higher Values Indicate Worse Pain — 4.24; 4.41; 4.27 Average daily pain score — p=0.5695
N/A N=80 Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Chronic Kidney Disease · Diabetes
Primary: Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks — 34.0; 44.6 percent difference in geometric mean…
N/A N=73 Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
Type II Diabetes
Primary: Percent (%) of Subjects Who Achieve a ≥ 0.5% Reduction in HbA1C at 24 Weeks or Last Visit From Baseline. — 81.8; 61.1 % of participants
Phase 2 N=204 To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change of Corneal Fluorescein Staining of the Inferior Cornea Region. — -1.00; -0.78; -0.78 units on a scale (Likert)
N/A N=301 Self-Retaining Retractor in Obese Patients Undergoing Cesarean Section
Pregnancy · Obese
Primary: Wound Infection or Disruption — 38; 37 participants
Phase 3 N=381 MultiPoint Pacing IDE Study
Heart Failure
Primary: Freedom From System-related Complications Through 9 Months Compared to an Objective Performance Criterion — 0.932 Event-Free Probability
Phase 2 N=834 A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
Migraine
Primary: Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose — 8.9; 5.6; 14.8; 21.4 percentage of participants
Phase 3 N=91 A Study in Japanese Participants With Moderate-to-Severe Psoriasis
Psoriasis
Primary: Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque…
N/A N=49 The Role of Parents in Adolescent Weight Loss
Adolescent Obesity
Primary: Body Mass Index — 29.89; 32.82 kilograms/meters squared — p=0.06
N/A N=312 Clinical Trials for Elderly Patients With Multiple Disease
Chronic Obstructive Pulmonary Disease (COPD) · Congestive Heart Failure (CHF) · Sleep Disordered Breathing (SDB)
Primary: Time to First Hospitalization — 255; 224 days — p=0.342
N/A N=1,100 A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
Osteoporotic Fractures · Osteoporosis, Postmenopausal
Primary: Non-vertebral Fracture Incidence — 70; 0 participants